Lea Eslava-Kim, PharmD

Lea Eslava-Kim, PharmD, is a Drug Information Specialist for MPR. She received her doctorate in pharmacy from the Ernest Mario School of Pharmacy, Rutgers University and completed her pharmacy residency at Clara Maass Medical Center. She is a licensed pharmacist.

All articles by Lea Eslava-Kim, PharmD

Drugs in the Pipeline

Baricitinib Improves Hair Regrowth in Alopecia Areata Trial

Lea Eslava-Kim, PharmD

March 4, 2021

Both doses of baricitinib met the primary end point, demonstrating statistically significant improvement in scalp hair regrowth compared with placebo.

News

FDA Clears Q-Collar Device for Athletes

Lea Eslava-Kim, PharmD

March 1, 2021

Of the 139 athletes who wore the Q-Collar, 77% showed no significant changes in the deeper tissues of the brain involved in the transmission of electrical nerve signals.

News

Amondys 45 Approved for Duchenne Muscular Dystrophy

Lea Eslava-Kim, PharmD

February 26, 2021

Treatment with casimersen led to a statistically significant increase in dystrophin production in skeletal muscle from baseline to week 48.

WORLDSymposium 2021

Arimoclomol Demonstrates Sustained Effect in Niemann-Pick Disease Type C

Lea Eslava-Kim, PharmD

February 9, 2021

Arimoclomol is a small molecule designed to amplify and sustain the cellular production of heat shock proteins, particularly HSP70, which targets protein misfolding and improves lysosomal function.

ATS Virtual Program 2020

First-in-Class Dual PDE Inhibitor Plus Tiotropium May Improve Lung Function in COPD

Lea Eslava-Kim, PharmD

August 10, 2020

Nebulized ensifentrine, when added to tiotropium, produced clinically meaningful and significant improvements in lung function and quality of life in patients with COPD.

News

Tivicay PD Approved for Pediatric HIV Patients

Lea Eslava-Kim, PharmD

June 16, 2020

The FDA has approved Tivicay PD (dolutegravir; Viiv Healthcare) tablets for oral suspension, for the treatment of HIV-1 infection in treatment-naïve or -experienced but integrase inhibitor-naïve pediatric patients aged ≥4 weeks and weighing at least 3kg, in combination with other antiretroviral agents.

News

Factors Contributing to Poor ART Adherence, HIV-1 Drug Resistance Explored

Lea Eslava-Kim, PharmD

June 15, 2020

HIV-positive patients in the United States face significant challenges associated with poor adherence to antiretroviral therapy (ART) and HIV-1 drug resistance, according to a study published in AIDS and Behavior.

News

Aging and HIV Treatment: Is Dose Adjustment Necessary?

Lea Eslava-Kim, PharmD

June 4, 2020

Antiretroviral drug dose adjustment based on age does not appear to be necessary in aging HIV patients, according to a pharmacokinetics study published in the British Journal of Clinical Pharmacology.

ACAAI 2019

GABA Agonists Not Linked to Increased Asthma, Allergic Rhinoconjunctivitis

Lea Eslava-Kim, PharmD

November 8, 2019

GABA agonists for chronic pain, such as gabapentin and pregabalin, were not associated with higher prevalence of allergic rhinoconjunctivitis and asthma.

AAO 2019

Novel Integrin Inhibitor Meets End Point in Dry Age-Related Macular Degeneration Study

Lea Eslava-Kim, PharmD

October 15, 2019

Intravitreal risuteganib demonstrated statistical significance compared to sham injection in patients with intermediate nonexudative age-related macular degeneration, according to new study.